New drugs approved by NMPA in the first half of 2020.

TextIn the first half of 2020
, NMPA approved 27 new drugs, including 17 imported drugs and 10 domestically produced drugsIn terms of drug types, it includes 13 drugs, 10 biological drugs, 3 Chinese medicines and 1 vaccine productOf the 5.1 new drugs approved for sale in China in the first half of 2020, FirstVoice Pharmaceuticals owns Abassup's Chinese interests, North Beihai Kangcheng owns The Chinese Interests of Naratini, and Fosun Pharma owns the Chinese rights of AvalupaIn addition, Asahi Kasei's pyrethyl and GSK's fenderaquinone hydrochloride slow release tablets are among the first to be listed in China, and a number of generic drugs have been approved in Chinafrom a corporate perspective, in the first half of 2020, Roche, Takeda, Sanofi and Concord Fermented Kirin have two new drugs approved for sale in ChinaAmong them, Roche's Emmita tolone is the first domesticapproved antibody conjugate drug (ADC), and atirezumab is the second PD-L1 drug approved in ChinaTakeda's Vibutuximis is the second ADC drug approved in China, six of the 17 imported drugs approved for the 2020 market are clinically urgently needed for overseas useIn terms of the number of days of approval, the average approval time for the remaining five drugs was 213 days, except for The Direct Approval of Perdaru singantis for clinical applicationAmong them, the tablets were approved for listing in China in just 115 daysapproved in the first half of 2020, the clinical needs of overseas drugThe following selection of some new drugs to do a brief introduction:Roche's mesto-beaded monomatox was approved in China in January 2020, mainly used for receiving the yew-enline-type joint quractal monovirus-based new auxiliary treatment of HER2-positive early breast cancer patients who still have the invasive lesions of sexually transmitted diseases, but also filled the Chinese HER2-positive breast cancer patients after the new auxiliary treatment of pathology did not reach complete mitigation (pCR) treatment gapthe indications were approved in the U.Sand the European Union in May 2019 and December 2019, respectively, achieving simultaneous approval for China and Europe V and Sanchi total alkaloid tablets are mainly used in combination with diet control and exercise to treat type 2 diabetes The drug, which has clinically proven efficacy similar to acapo sugar, is the first new chinese medicine for diabetes approved in the past 10 years Haussen's amatinib tablets are mainly used in adult patients with locally advanced or metastatic non-small cell lung cancer who have been treated with or after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) and have been tested positive for EGFR T790M mutations This is the world's third generation of eGFR-TKI innovative drug, and the first domestic ally three-generation EGFR-TKI drug tium-butyl benzodiazepine tablets are mainly used to treat dance diseases associated with Huntington's disease and delayed movement disorders in adults This is the first FDA-approved product of the xenon generation and the second drug in history to target dance disease linked to Huntington's disease China is the second country after the United States to approve the drug, and the first chinese-made drug Zebutini, , is the first localdrug to be developed and developed by the U.S FDA, and the first domestically available btK inhibitor At present, Baiji Shenzhou has submitted in the European Union Zebtinib for the treatment of Patients with Fahrenheit polycylobin emis Sanofi Dupilumab injection is the world's first targeted biologic agent approved for the treatment of moderate and severe adhesitis in adults Dupixent, a monoclonal antibody drug targeting IL-4R, was first approved by the FDA in March 2017 and has global sales of 2,074 million euros in 2019, with Sanofi planning to turn it into a bombshell with annual sales of more than 10 billion euros .